PT1235799E - Forma polimorfica de atorvastatina-calcio - Google Patents

Forma polimorfica de atorvastatina-calcio

Info

Publication number
PT1235799E
PT1235799E PT00978744T PT00978744T PT1235799E PT 1235799 E PT1235799 E PT 1235799E PT 00978744 T PT00978744 T PT 00978744T PT 00978744 T PT00978744 T PT 00978744T PT 1235799 E PT1235799 E PT 1235799E
Authority
PT
Portugal
Prior art keywords
polymoric
atorvastatin
calcium
pharmaceutical compositions
dosage forms
Prior art date
Application number
PT00978744T
Other languages
English (en)
Inventor
Revital Lifshitz
Judith Aronhime
Ayalon Ari
Levinger Michal
Roytblat Sofia
Niddam Valerie
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PT1235799E publication Critical patent/PT1235799E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
PT00978744T 1999-11-17 2000-11-16 Forma polimorfica de atorvastatina-calcio PT1235799E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16615399P 1999-11-17 1999-11-17

Publications (1)

Publication Number Publication Date
PT1235799E true PT1235799E (pt) 2005-05-31

Family

ID=22602039

Family Applications (2)

Application Number Title Priority Date Filing Date
PT00978744T PT1235799E (pt) 1999-11-17 2000-11-16 Forma polimorfica de atorvastatina-calcio
PT04027375T PT1535613E (pt) 1999-11-17 2000-11-16 Processo de preparação de uma forma polimórfica de atorvastatina de cálcio

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT04027375T PT1535613E (pt) 1999-11-17 2000-11-16 Processo de preparação de uma forma polimórfica de atorvastatina de cálcio

Country Status (20)

Country Link
EP (3) EP1535613B1 (pt)
JP (2) JP2003514798A (pt)
KR (1) KR20020063190A (pt)
CN (1) CN1423634A (pt)
AT (2) ATE288893T1 (pt)
AU (1) AU783002B2 (pt)
CA (1) CA2392096C (pt)
CZ (1) CZ20021642A3 (pt)
DE (2) DE60018100T2 (pt)
ES (2) ES2349364T3 (pt)
HR (1) HRP20020429B8 (pt)
HU (1) HUP0203257A3 (pt)
IL (2) IL149681A0 (pt)
PL (1) PL355805A1 (pt)
PT (2) PT1235799E (pt)
SI (2) SI1535613T1 (pt)
SK (1) SK286789B6 (pt)
WO (1) WO2001036384A1 (pt)
YU (1) YU35802A (pt)
ZA (1) ZA200203755B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
JP2004513956A (ja) * 2000-11-03 2004-05-13 テバ　ファーマシューティカル　インダストリーズ　リミティド アトルバスタチンヘミカルシウムｖｉｉ型
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0302519A3 (en) 2000-12-27 2008-10-28 Teva Pharma Crystalline forms of atorvastatin, process for their preparation and pharmaceutical compositions containing them
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
UA74075C2 (en) * 2001-06-29 2005-10-17 Warner Lambert Co NOVEL CRYSTALLINE FORMS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-b, d-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1??-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)(ATORVASTATIN) (VARIANTS)
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
CZ2004126A3 (cs) 2001-07-30 2004-12-15 Dr. Reddy's Laboratories Limited Krystalické formy VI. A VII. vápenaté soli atorvastatinu
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
ES2241507T1 (es) * 2002-02-15 2005-11-01 Teva Pharmaceutical Industries Ltd. Nuevas formas de cristal de atorvastatina semicalcica y procedimientos para su preparacion, asi como nuevos procedimientos para la preparacion de las formas i, viii y ix de atorvastatina semicalcica.
IL163594A0 (en) 2002-02-19 2005-12-18 Teva Pharma Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
US20060035941A1 (en) * 2002-06-13 2006-02-16 Guang-Pei Chen Calcium salts of indole derived statins
GB0218781D0 (en) * 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
AU2003297594A1 (en) * 2002-11-28 2004-06-23 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
DE202005020841U1 (de) 2004-09-28 2006-08-31 Teva Pharmaceutical Industries Ltd. Formen von Atorvastatin-Calcium, die im wesentlichen frei von Verunreinigungen sind
EP1716114A1 (en) 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
NZ554541A (en) 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
EP1814541A4 (en) 2004-11-22 2009-10-28 Dexcel Pharma Technologies Ltd STABLE ATORVASTATIN FORMULATIONS
CA2499047A1 (en) 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
CA2619040C (en) 2005-08-15 2015-02-10 Arrow International Limited Crystalline and amorphous sodium atorvastatin
CA2619486C (en) 2005-08-15 2015-05-12 Arrow International Limited Crystalline and amorphous sodium atorvastatin
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
WO2007057755A1 (en) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid magnesium
MX2007014329A (es) * 2005-12-13 2008-03-19 Teva Pharma Forma cristalina de hemi-calcio de atorvastatina y procesos para la preparacion de ella.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2007096903A2 (en) * 2006-02-22 2007-08-30 Matrix Laboratories Ltd New crystalline form of atorvastatin hemi-calcium
EP2132171A4 (en) * 2007-03-02 2010-11-17 Dong A Pharm Co Ltd NOVEL CRYSTALLINE FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US20100260851A1 (en) * 2007-07-11 2010-10-14 Actavis Group Ptc Ehf Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
US8785461B2 (en) 2008-02-08 2014-07-22 Generics [Uk] Limited Process for preparing bosentan
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
SI2373609T1 (sl) * 2008-12-19 2013-12-31 Krka, D.D., Novo Mesto Uporaba amfifilnih spojin za kontrolirano kristalizacijo statinov in intermediatov statinov
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN102249978A (zh) * 2011-06-09 2011-11-23 浙江金立源药业有限公司 阿托伐他汀钙的ky晶型及制备方法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN105085362B (zh) * 2015-09-18 2018-01-05 浙江海森药业有限公司 高纯度结晶型阿托伐他汀钙的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2150372C (en) * 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
EP0848705B1 (en) * 1995-07-17 2001-11-07 Warner-Lambert Company Crystalline r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Also Published As

Publication number Publication date
SI1235799T1 (en) 2005-06-30
IL149681A (en) 2007-06-17
SK286789B6 (sk) 2009-05-07
DE60018100T2 (de) 2005-09-15
EP1535613A2 (en) 2005-06-01
JP2009102439A (ja) 2009-05-14
CA2392096A1 (en) 2001-05-25
EP2206497A1 (en) 2010-07-14
EP1235799A4 (en) 2003-05-28
HRP20020429A2 (en) 2004-04-30
CA2392096C (en) 2008-07-15
WO2001036384A1 (en) 2001-05-25
ES2349364T3 (es) 2010-12-30
EP1235799B1 (en) 2005-02-09
DE60044884D1 (de) 2010-10-07
DE60018100D1 (en) 2005-03-17
EP1535613A3 (en) 2005-08-31
KR20020063190A (ko) 2002-08-01
ZA200203755B (en) 2004-05-26
ATE288893T1 (de) 2005-02-15
IL149681A0 (en) 2002-11-10
HRP20020429B1 (en) 2006-05-31
EP1235799A1 (en) 2002-09-04
SK6742002A3 (en) 2003-05-02
PT1535613E (pt) 2010-10-04
PL355805A1 (en) 2004-05-17
AU1617301A (en) 2001-05-30
YU35802A (sh) 2005-07-19
HUP0203257A3 (en) 2003-05-28
ES2234699T3 (es) 2005-07-01
CZ20021642A3 (cs) 2003-05-14
HRP20020429B8 (en) 2007-03-31
AU783002B2 (en) 2005-09-15
SI1535613T1 (sl) 2010-12-31
EP1535613B1 (en) 2010-08-25
ATE478665T1 (de) 2010-09-15
CN1423634A (zh) 2003-06-11
HUP0203257A2 (hu) 2003-01-28
JP2003514798A (ja) 2003-04-22

Similar Documents

Publication Publication Date Title
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
ATE296619T1 (de) Feste orale dosierungsform von simethicon
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
DE69907977D1 (de) Pyrrolobenzodiazepine
IL150223A (en) Lipopeptides and pharmaceuticals containing them
ES2193337T3 (es) Utilizacion de sales de estroncio para el tratamiento de la artrosis.
EA199900373A2 (ru) Фармацевтические композиции
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
EE05020B1 (et) Glburiidi ravimkoostis
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
SE9901077D0 (sv) Novel use
BR9407743A (pt) Composiçao oral de peróxido de cálcio-bicarbonato
SE9801494D0 (sv) Novel use
ITMI20011637A0 (it) Composizione farmaceutica contenente citalopram
DE50014763D1 (de) Anlage zur fertigung von halbleiterprodukten
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
ITMI20011284A0 (it) Composizione farmaceutica per il trattamento dell'iperfosfatemia
PT102642A (pt) Composicao farmaceutica de dosagem unica diaria contendo brivudine
DE60217720D1 (de) Kurkumin-zusammensetzung zur heilung von dickdarmpolypen
ATA171599A (de) Pharmazeutische zusammensetzung zur abdeckung des grundbedarfs an vitaminen